Opendata, web and dolomites

MECADISTEM

A new and innovative method to extract adipose Stromal Vascular Fraction: Application in post-prostatectomy erectile dysfunction

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MECADISTEM project word cloud

Explore the words cloud of the MECADISTEM project. It provides you a very rough idea of what is the project "MECADISTEM" about.

commercial    adult    medical    expecting    money    regenerating    clinical    view    damaged    quality    milestones    erectile    damages    roi    substantial    collagenase    million    treat    dysfunction    cancer    therapies    financial    savings    time    rp    efficient    alternatives    cure    finalise    hire    unmet    centrifugation    post    prostatectomy    svf    adipose    hold    proven    surgeons    tissue    point    people    cell    isolate    men    profits    validated    methodology    preparation    tools    cellular    constraints    cells    complication    patients    operations    grinding    12    filtration    stemcis    form    stem    kit    imposed    ed    single    enzymatic    secure    extract    frequent    surgical    market    avoiding    feasibility    mecadistem    vascular    treatment    impairs    enzymes    urologists    digestion    candidate    extracted    repair    tissues    stromal    28    radical    once    progenitor    prostate    gain    life    simply    mechanically    preclinical    fraction    shown    minutes   

Project "MECADISTEM" data sheet

The following table provides information about the project.

Coordinator
STEMCIS SAS 

Organization address
address: 2 RUE MAXIME RIVIERE
city: SAINTE CLOTILDE
postcode: 97490
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.stemcis.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STEMCIS SAS FR (SAINTE CLOTILDE) coordinator 50˙000.00

Map

 Project objective

Erectile dysfunction (ED) is a significant and common medical problem which impairs quality of life of men and their partners. ED is a frequent complication after a radical prostatectomy (RP) due to surgical treatment for prostate cancer. For this condition, ED represents a significant unmet medical need, since there is no efficient treatment to repair the cellular damages following a RP. Clinical implementation of stem cell treatment represents a potential candidate for ED treatment after RP. Adult progenitor cells extracted from adipose tissue, called Stromal Vascular Fraction (SVF) have shown promising results in preclinical and clinical studies to treat post-RP ED. STEMCIS has developed a unique kit to isolate the adipose cells which hold the potential to cure post-prostatectomy ED by regenerating the damaged tissues. MECADISTEM comes in the form of a single-use kit that includes all the tools necessary to simply and rapidly (less than 30 minutes) extract adipose tissue progenitor cells mechanically (grinding, centrifugation, filtration). Compared to the state-of-the-art alternatives using “collagenase (enzymatic) digestion”, MECADISTEM does not require the use of enzymes, avoiding the problems and constraints imposed by the use of this enzymatic digestion and offering substantial time and money savings, on both technical and surgical operations. Having validated this methodology in preclinical study, this project is planned to finalise the development and market preparation of this kit. In this Phase 1 Feasibility Study, we aim to evaluate the main milestones of the project from a technical, commercial and financial point of view. Once in the market, MECADISTEM will be used by urologists and surgeons to cure ED in patients following a RP, where the current therapies have not been proven effective. It will secure the growth for STEMCIS, expecting to gain over €12 million in profits, hire 6 new people and reach a ROI of €6.28 from this project after 5 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MECADISTEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MECADISTEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

GREEN WHS (2019)

NATURE FRIENDLY WATER HYDRAULIC STEERING SYSTEM

Read More  

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More